SightLife Surgical Rebrands as CorneaGen, Offers New Products

April 13, 2018: By Jon Swedien

SightLife Surgical announced April 12 that it has changed its name to CorneaGen.

The Seattle-based subsidiary of the nonprofit SightLife also announced it has three new product offerings:

–Tissue storage media with antifungal amphotericin B (Ampho B), which is used to combat rising rates of post-transplant fungal infections;

–The Geuder Preloaded Glass Cannula for Descemet’s membrane endothelial keratoplasty (DMEK);

–Intacs corneal implants for keratoconus.

The company in the past 18 months begun offering more products and services aimed at transforming how corneal surgeons treat the cornea, President and CEO Monty Montoya said. The company decided to change its name to reflect its focus, Montoya said.

In March, the company also acquired the KAMRA corneal inlay from AcuFocus.

Regarding Ampho B, CorneaGen said surgeons across the US have long requested it. CorneaGen is now the first US company to offer storage media with Ampho B, the company said.

The Geuder Preloaded Glass Cannula for DMEK is the first specifically designed for preloaded cornea tissue, CorneaGen said. The device uses a locking system that minimizes damage to the tissue during transport, CorneaGen said.

Intacs corneal implants are designed to reduce or eliminate myopia and astigmatism in keratoconus patients, CorneaGen said. Intacs corneal implants help restore functional vision and potentially defer the need for a corneal transplant. CorneaGen said it has signed an exclusive US distribution agreement for Intacs with Addition Technology, an AJL Ophthalmics subsidiary.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023